The cutaneous lymphatic system plays an important role in the maintenance of tissue fluid homeostasis, in the afferent phase of the immune response, and in the metastatic spread of skin cancers. However, the lymphatic system has not received as much scientific attention as the blood vascular system, largely due to a lack of lymphatic-specific markers and to the dearth of knowledge about the molecular regulation of its development and function. The recent identification of genes that specifically control lymphatic development and the growth of lymphatic vessels (lymphangiogenesis), together with the discovery of new lymphatic endothelium-specific markers, have now provided new insights into the molecular mechanisms that control lymphatic growth and function. Moreover, studies of several genetic mouse models have set the framework for a new molecular model for embryonic lymphatic vascular development, and have identified molecular pathways whose mutational inactivation leads to human diseases associated with lymphedema. These scientific advances have also provided surprising evidence that malignant tumors can directly promote lymphangiogenesis and lymphatic metastasis, and that lymphatic vessels play a major role in cutaneous inflammation and in the cutaneous response to UVB irradiation.
Apart from the cardiovascular system, higher vertebrates also possess a lymphatic system that consists of the lymphatic vessels and the lymphoid organs that include lymph nodes, tonsils, Peyer's patches, spleen, and thymus. Whereas the cardiovascular system forms a closed circle around which blood is pumped by the heart, the lymphatic system comprises a oneway, open-ended network without a central driving force. Lymph, a proteinrich exudate from blood vessels, is taken up by the lymphatic capillaries in the tissue. From there it is returned to the venous circulation via the larger collecting lymphatic vessels and the thoracic duct, which connects the lymphatic system to the inferior vena cava (Figure 1 ). The pressure gradients to move lymph through the vessels result from skeletal muscle action, respiratory movement, and contraction of smooth muscle cells in vessel walls. The lymphatic system also contributes to the immune surveillance of the body. Lymphatic vessels transport immune cells -including lymphocytes and antigen-presenting dendritic cellsfrom the skin to regional lymph nodes, where specific immune responses are initiated. In addition, the lacteal lymphatic vessels of the intestine are involved in the uptake of dietary fat and of the fat-soluble vitamins A, D, E, and K from the digestive system. However, recent scientific discoveries have revealed that the lymphatic system also plays a major role in a number of pathologic conditions, including lymphedema, inflammatory diseases, and tumor metastasis.
Lymphatic vessels are present in almost all tissues but are absent from avascular structures such as the epidermis, hair, nails, cartilage, and cornea, and from some vascularized organs such as the brain and retina. In the skin, the superficial lymphatic plexus collects lymph from lymphatic capillaries that can extend into the dermal papillae. These lymphatic capillaries are lined by a single, non-fenestrated layer of overlapping endothelial cells, and -in contrast to blood vessels -lack a continuous basement membrane as well as pericyte or smooth muscle cell coverage. Lymphatic endothelial cells (LECs) are connected to the surrounding extracellular matrix by specialized fibrillin-containing anchoring filaments (Gerli et al., 2000) . Upon increase of interstitial fluid pressure, these filaments exert tension on LECs, thereby widening the capillary lumen and opening the overlapping cell junctions, which enables the uptake of fluid, macromolecules, and cells. The larger collecting lymphatic vessels in the lower dermis and upper subcutis are surrounded by a basement membrane and by a layer of smooth muscle cells that contribute to lymph propulsion. They contain luminal valves to ensure unidirectional fluid transport.
Embryonic development
The first description of the lymphatic system dates back to the seventeenth century, when the Italian anatomist Gasparo Aselli identified lymphatic vessels as ''milky veins'' in the mesentery of a ''well-fed '' dog (Asellius, 1627) . However, the developmental origin of lymphatic vessels remained unclear until Florence Sabin proposed in 1902 -based upon ink-injection experiments in pigs -that endothelial cells bud off from the veins during early embryonic development and form primitive lymph sacs. The peripheral lymphatic system then originates from these primary lymph sacs by endothelial sprouting into the surrounding tissues and organs, where local capillaries are formed (Sabin, 1902) . This model was challenged in 1910 by Huntington and McClure who alternatively suggested that lymph sacs ariseindependently of the veins -from mesenchymal precursor cells (lymphangioblasts), with consecutive establishment of venous connections (Huntington and McClure, 1910) . Recent studies in genetically engineered mouse models have now provided clear evidence for the origin of the mammalian lymphatic system from embryonic veins (Oliver, 2004) , and they have also identified some of the molecular determinants that control the step-wise process of lymphatic competence, commitment, differentiation and maturation ( Figure 2 ).
Novel molecular markers of lymphatic endothelium
Major advances in lymphatic research have been made possible by the recent establishment of defined cultures of blood vascular endothelial cells (BECs) and LECs isolated from human skin (Kriehuber et al., 2001; Makinen et al., 2001; Podgrabinska et al., 2002; Hirakawa et al., 2003) . These cells maintain their lineage-specific differentiation even after several passages in vitro. Comparative microarray analyses of their specific transcriptomes revealed that the majority of all genes investigated (appr. 98%) were
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Peripheral tissue capillaries Figure 1 . Schematic illustration of the blood vascular and lymphatic system. The blood vascular system is a circular and closed system, whereas the lymphatic system is open-ended and linear. Fluids, macromolecules, and cells extravasated from blood capillaries enter lymphatic capillaries in peripheral tissues and are then transported via the larger collecting lymphatic vessels and the thoracic duct back to the blood vascular system for recirculation. 
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Figure 2. Current model of the stepwise embryonic development of the mammalian lymphatic system. During early vascular development, all endothelial cells of the embryonic cardinal vein express two important lymphatic markers, lymphatic vascular endothelial hyaluronan receptor (LYVE-1) and VEGFR-3, and display lymphatic competence. Stimulation by a yet unidentified inductive mesenchymal signal leads to induction of the transcription factor Prox1 in a subset of endothelial cells that become committed to the lymphatic lineage. These cells bud off from the vein and migrate into the surrounding tissue to form primitive lymph sacs. During this process, they adopt the expression of additional lymphatic lineage markers. The formation of a mature lymphatic network continues through the first postnatal days.
expressed at comparable levels by the two endothelial cell types (Petrova et al., 2002; Hirakawa et al., 2003) , corroborating their close genetic relationship. However, these studies have also identified numerous, previously unknown lineage-specific markers for blood vascular and lymphatic endothelium (Table 1) . Whereas the specific function of the majority of the differentially expressed genes still remains unknown, the study of several lymphatic-specific molecules has provided important new insights into the molecular control of lymphatic development and function (Table 2) . Vascular endothelial growth factor receptor-3 (VEGFR-3), also known as Flt4, was the first lymphatic-specific growth factor receptor identified (Kaipainen et al., 1995) . VEGFR-3 is a member of the fms-like tyrosine kinase family and specifically binds vascular endothelial growth factor (VEGF)-C and VEGF-D, but not VEGF-A. During early embryonic development, VEGFR-3 is expressed both (Barsky et al., 1983; Petrova et al., 2002) Collagen XVIII Basement membrane molecule À/(+) 5 ++ (Petrova et al., 2002; Hirakawa et al., 2003) PAL-E Caveolae-associated glycoprotein? À ++ (Schlingemann et al., 1985; Niemela et al., 2005) BV, blood vessel; CCL, CC chemokine ligand; LV, lymphatic vessel; LYVE-1, lymphatic vascular endothelial hyaluronan receptor-1; PAL-E, pathologische anatomie leiden-endothelium; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
1 VEGFR-3 expression was also found on some blood capillaries during tumor neovascularization and in wound granulation tissue (Valtola et al., 1999; Paavonen et al., 2000) . Neuropilin-2 is also expressed in veins (Yuan et al., 2002) .
3
After activation, both blood vascular and lymphatic endothelial cells strongly express CCL20 (Kriehuber et al., 2001 ).
4
CD34 expression has also been found on lymphatic endothelial cells (Sauter et al., 1998; Kriehuber et al., 2001) .
5
Peripheral lymphatic vessels sometimes have an incomplete basement membrane, large collecting vessels a complete one.
www.jidonline.org 2169 in developing venous and in presumptive lymphatic endothelia. In normal adult tissues, VEGFR-3 expression is largely restricted to the lymphatic endothelium (Kaipainen et al., 1995; Partanen et al., 2000) . However, VEGFR-3 expression has also been detected on some blood capillaries associated with tumor neovascularization or with wound granulation tissue (Partanen et al., 1999; Paavonen et al., 2000) ; therefore VEGFR-3 alone is not a sufficiently specific marker for lymphatic vessels.
The transcription factor Prox1 is a homolog of the Drosophila homeobox gene prospero (Oliver et al., 1993) . At present, it is considered as the most specific lineage marker for lymphatic endothelium -among endothelial cells, it is exclusively detected in lymphatic vessels of adult tissues and tumors (Oliver and Detmar, 2002) . During lymphatic development, Prox1 expression is induced in lymphatically ''competent'' endothelial cells at one side of the cardinal vein around mouse embryonic day (E) 9.5-E10.5 by a presently unknown signal, leading to lymphatic commitment and specification ( Figure 2 ). In Prox1 null mice, budding and sprouting of these cells from the veins is arrested prematurely at around E11.5-E12.0, and as a result, these mice completely lack lymphatic vasculature (Wigle and Oliver, 1999) (Table 2 ). In Prox1 null mice, the budding endothelial cells fail to express lymphatic endothelial markers (Wigle et al., 2002) . Conversely, ectopic expression of Prox1 in differentiated BECs is sufficient to reprogram these cells to adopt a lymphatic phenotype (Hong et al., 2002; Petrova et al., 2002) . Prox1 þ /À mice die within 2-3 days after birth in all of the tested genetic backgrounds except one (Wigle and Oliver, 1999) , in which they develop chylous ascites and -interestinglyadult onset obesity, suggesting a link between impaired lymphatic function and obesity (Harvey et al., 2005) . Lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1), a homologue of the blood vascular endothelium-specific hyaluronan receptor CD44 (Banerji et al., 1999) , was identified as a specific cell surface protein of LECs and macrophages. It is presumably involved in hyaluronan metabolism (Jackson, 2004) but its exact function remains unclear -LYVE-1-deficient mice have no obvious lymphatic vascular malfunctions or morphological abnormalities (G. Thurston, personal communication). LYVE-1 is the first marker of lymphatic endothelial competence during development ( Figure 2) ; in the mature vasculature, LYVE-1 expression remains high in lymphatic capillaries while being downregulated in the collecting lymphatic vessels (Makinen et al., 2005) .
Podoplanin, a mucin-type transmembrane glycoprotein, is expressed by lymphatic but not by BECs in vivo and in vitro (Wetterwald et al., 1996; Breiteneder-Geleff et al., 1999; Kriehuber et al., 2001; Petrova et al., 2002; Hirakawa et al., 2003) . Its biological function is currently unknown, although in vitro studies indicated that podoplanin may be involved in mediating cell motility by promoting rearrangement of the actin cytoskeleton (Schacht et al., 2003) . Podoplanin null mice display lymphedema, dilated lymphatic vessels, and impaired lymphatic transport, and they die at birth of respiratory failure Schacht et al., 2003) . Therefore, to further study the role of podoplanin in postnatal life, it will be essential to generate tissue-specific knockout mice. Human podoplanin is recognized by the D2-40 antibody (Schacht et al., 2005) and is also expressed by several non-endothelial cells (Schacht et al., 2005) and by squamous cell carcinomas and certain germ cell tumors (Martin-Villar et al., 2005; Schacht et al., 2005) , suggesting a potential role in tumor progression.
The chemokine CCL21, also known as secondary lymphoid chemokine or Exodus-2, is secreted by lymphatic endothelium, but not blood vascular endothelium (Kriehuber et al., 2001) , and interacts with the CC chemokine receptor 7. It mediates homing of lymphocytes and migration of antigenstimulated dendritic cells from the tissues into the lymphatic vessels and the secondary lymphatic organs, thus playing an important role in immunoregulatory and inflammatory processes. CCL21 has also been shown to enhance lymph node metastasis of CCR-7-expressing malignant melanoma xenotransplants (Wiley et al., 2001) . Desmoplakin is a cytoplasmic anchor protein of lymphatic endothelial adherens junctions that connects intermediate filaments to the plasma membrane. Blood vessels do not express desmoplakin (Ebata et al., 2001) .
Using gene array analysis of LECs versus BECs, a large number of previously unknown vascular lineagespecific genes have been identified (Petrova et al., 2002; Hirakawa et al., 2003) . Newly identified LEC-specific genes include macrophage mannose receptor 1, plakoglobin, integrin a9, and the chemokine CCL20. The latter, however, becomes strongly expressed in both blood vascular and LECs upon activation (Kriehuber et al., 2001) . BECspecific genes include VEGFR-1, neuropilin-1, the hyaluronan receptor CD44, endoglin, adhesion molecules such as ICAM-1, integrin a5 and N-cadherin, and several basement membrane, and extracellular matrix components (collagen IV, versican, laminin, collagen XIII) (Hirakawa and Detmar, 2004) . Other blood vascular markers include PAL-E (Skobe and Detmar, 2000) and CD34 (Hirakawa et al., 2003) . The roles of most of these molecules for the functional regulation and physiological maintenance of the two types of vasculature remain to be elucidated. Orlandini et al., 1996; Achen et al., 1998) , and are presently the only known ligands for this receptor. VEGF-C promotes proliferation, migration, and survival of cultured human LECs . Importantly, transgenic mice overexpressing VEGF-C or VEGF-D in the skin show hyperplasia of cutaneous lymphatic vessels (Jeltsch et al., 1997; Veikkola et al., 2001) (Table 2) , whereas VEGF-C null mouse embryos completely lack a lymphatic vasculature and die prenatally of fluid accumulation within the tissues (Karkkainen et al., 2004) . In these mice, the lymphatically committed venous endothelial cells express Prox1 but are unable to migrate out to form the initial lymph sacs. These findings indicate that LEC specification and subsequent migration are two separate events, and that VEGF-C signalling is indispensable for the latter (Figure 2 Inactivation of VEGFR-3 causes cardiovascular failure and embryonic death at E9.5 before the emergence of lymphatic vessels (Dumont et al., 1998) , hampering the analysis of its role in lymphatic development. Nonetheless, VEGFR-3 mutations have been identified in Chy mutant mice that are characterized by cutaneous lymphedema (Karkkainen et al., 2001), providing support for an important role of this gene in lymphatic development and function. The distinct contributions of VEGFR-3 versus VEGFR-2 towards lymphangiogenesis remain at present unclear, because VEGF-C and VEGF-Dafter enzymatic cleavage -also activate VEGFR-2, which is expressed by LECs (Kriehuber et al., 2001; Veikkola et al., 2001; Hirakawa et al., 2003; Hong et al., 2004b) . Importantly, however, skin-specific overexpression of a VEGFR-3-specific mutant of VEGF-C (VEGF-C156S; Joukov et al., 1998) in transgenic mice revealed that activation of VEGFR-3 signal transduction is sufficient to promote lymphangiogenesis .
The possible contribution of VEGF-A (also named VEGF or vascular permeability factor), to lymphangiogenesis has been a matter of controversy. VEGF-A was discovered in 1983 as the first member of the VEGF family (Senger et al., 1983) and activates VEGFR-1 and VEGFR-2. Although VEGF-A cannot substitute for VEGF-C to rescue the phenotype of VEGF-Cdeficient mice (Karkkainen et al., 2004) , several recent studies have established a role of the VEGF-A/ VEGFR-2 signalling pathway in lymphangiogenesis. VEGF-A potently induces proliferation of LECs in vitro (Hirakawa et al., 2003) , and injection of adenoviral murine VEGF-A164 resulted in pronounced and persistent in vivo lymphangiogenesis in mouse ear skin (Nagy et al., 2002) . Targeted overexpression of murine VEGF-A164 in the skin of transgenic mice enhanced lymphangiogenesis as well as angiogenesis during tissue repair and in skin inflammation (Kunstfeld et al., 2004; Hong et al., 2004b) . These effects could be inhibited by a specific VEGFR-2 blocking antibody, indicating that VEGF-A signalling through VEGFR-2 is important for lymphangiogenesis. However, indirect effects of VEGF-A, via attraction of inflammatory cells producing VEGF-C and -D (Cursiefen et al., 2004; Baluk et al., 2005) might also contribute to VEGF-A's lymphangiogenic activity (Hirakawa et al., 2005) .
Neuropilins are non-kinase type I transmembrane proteins that play an important role in axon guidance within the nervous system as semaphorin receptors (Neufeld et al., 2002) . Whereas neuropilin-1 is predominantly expressed in arterial endothelial cells, neuropilin-2 is expressed in veins and lymphatic capillaries (Karkkainen et al., 2001; Hong et al., 2002; Yuan et al., 2002) . It serves as a co-receptor for several VEGF family members including VEGF-A165, placental growth factor, and VEGF-C (Gluzman-Poltorak et al. , 2000; Karkkainen et al., 2001) . In addition to neural defects, neuropilin-2-deficient mice show a severe reduction of small lymphatic vessels, whereas they develop normal arteries, veins, and larger collecting lymphatic vessels (Yuan et al., 2002) . The finding that neuropilin-2 binds VEGF-C raises the possibility that VEGF-C signalling through VEGFR-3 may be enhanced by neuropilin-2, similar to the Nrp1-mediated promotion of VEGF-A signalling to VEGFR-2 (Soker et al., 1998) .
The angiopoietin signalling system is indispensable for normal blood vessel development as demonstrated by several genetic mouse models (Dumont et al., 1994; Suri et al., 1996; Maisonpierre et al., 1997) . Angiopoietin-1 (Ang1), an activating ligand for the endothelial-specific receptor tyrosine kinase Tie2 (tyrosine kinase with immunoglobulin-like loop and epidermal growth factor homology domains-2) , induces lymphangiogenesis in the mouse cornea and -after adenoviral gene transfer -in other adult mouse tissues (Tammela et al., 2005) . Transgenic mice overexpressing Ang1 in the skin show cutaneous lymphatic hyperplasia (Tammela et al., 2005) . The mechanism of these effects remains unclear. Tie2 is expressed in cultured LECs (Kriehuber et al., 2001; Petrova et al., 2002) and in the lymphatic vessels of mice Tammela et al., 2005) , suggesting that Ang1 might exert direct effects on lymphatic endothelium. However, treatment with soluble VEGFR-3 inhibited the effects of virally delivered Ang1 in mice, and Ang1 stimulation of LECs resulted in upregulation of VEGFR-3 in vitro and in vivo (Tammela et al., 2005) , indicating that Ang1 also acts indirectly via the VEGF-C/VEGFR-3 pathway. Angiopoietin-2, considered to be an antagonist of Tie2 (Maisonpierre et al., 1997) , also appears to be needed for the normal formation of the lymphatic vasculature because angiopoietin-2-deficient mice have chylous ascites, peripheral edema, and abnormal patterning of lymphatic vessels (Gale et al., 2002) . Interestingly, these defects, but not the blood vascular phenotype, can be rescued by Ang1 (Gale et al., 2002) . Thus, angiopoietin-2 might act like Ang1 as an agonist of Tie2 in lymphangiogenesis, while it is an (contextdependent) antagonist of Tie2 in angiogenesis.
Hepatocyte growth factor (HGF, also known as scatter factor) was recently identified as a potent lymphangiogenesis factor (Kajiya et al., 2005) . HGF promotes proliferation, migration, and tube formation of LECs via its receptor HGF-R. HGF-induced LEC proliferation was abolished by an HGF-R blocking antibody but not by blockade of VEGFR-3, indicating that HGF exerts its effects independently of the VEGFR-3 pathway. The promigratory effects of HGF are in part mediated by the integrin a9, which is specifically expressed by LECs and is required for normal lymphatic function (Huang et al., 2000) . Overexpression of HGF in transgenic mice as well as subcutaneous delivery of this growth factor resulted in increased numbers and enlargement of lymphatic vessels. These effects were not inhibited by a VEGFR-3 blocking antibody (Kajiya et al., 2005) , demonstrating that HGF can directly promote lymphangiogenesis in vivo.
Additional lymphangiogenic factors. Fibroblast growth factor-2 (FGF-2) was one of the first angiogenic factors identified and the role of FGFs in vascular development has been well characterized (Auguste et al., 2003) . FGF-2 also promotes lymphatic vessel growth -in addition to blood vessel growth -in the mouse cornea assay by inducing VEGF-C secretion from blood vascular endothelial and perivascular cells (Kubo et al., 2002; Chang et al., 2004) . FGF-2 might also directly act via its receptor FGFR-3, which is upregulated by Prox1 in lymphatic endothelium (Shin et al., 2005) . FGF-2 enhances migration and proliferation of primary LECs in vitro, and the promigratory effect could not be abrogated by neutralization of VEGFR-3, raising the possibility that FGF-2 might also function independently of the VEGF-C/VEGFR-3 pathway (Shin et al., 2005) . In addition, recent studies have suggested that platelet-derived growth factor-BB and insulin-like growth factors 1 and 2 might also induce lymphangiogenesis in the mouse corneal assay (Bjorndahl et al., 2005) , but their potential effects on skin lymphangiogenesis remain unclear. Likely, several lymphangiogenic growth factors work together in a complex way, contributing to the process of lymphatic vessel formation and growth in physiological or pathological conditions (Figure 3 ).
Genetic basis of lymphedema and new molecular therapies
Lymphedema is caused by insufficient lymph transport owing to lymphatic hypoplasia, impaired lymphatic function, or obstruction of lymph flow. Primary lymphedema is characterized by dilated lymphatic capillaries and interstitial accumulation of lymph fluid. In some families, congenital lymphedema is linked to the VEGFR-3 locus on distal chromosome 5q, and missense mutations in the VEGFR-3 gene have indeed been identified in several cases of hereditary, early-onset lymphedema (Witte et al., 2001) . Recent studies have identified additional mutations in other genes that are associated with different human lymphedema syndromes. In lymphedema-distichiasis, an autosomal-dominant disorder with congenital lymphedema and double rows of eyelashes (distichiasis), inactivating mutations of the FOXC2 gene, a member of the forkhead/winged-helix family of transcription factors, were identified in several families (Fang et al., 2000) . Moreover, mutations of the SOX18 gene on chromosome 20q13, a SRYrelated transcription factor, cause recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia syndrome. Mutations in the DNA-binding domain of SOX18 have been found in the recessive form of the disease whereas the dominant hereditary form is caused by a heterozygous nonsense mutation of the transactivation domain (Irrthum et al., 2003) . An involvement of Sox18 in lymphatic vessel development is further supported by the phenotype of ragged mice that develop lymphedema and also show abnormalities of the hair coat (Table 2) .
Based on its potent lymphangiogenic effect, VEGF-C has been tested for gene and protein therapy of lymphedema in animal models. Adenoassociated virus-mediated VEGF-C gene therapy promoted lymphatic vessel generation in the skin of Chy lymphedema mice (Karkkainen et al., 2001) . Importantly, VEGF-C156S, a mutant form of VEGF-C that selectively activates VEGFR-3, successfully induced the formation of a functional cutaneous lymphatic vessel network without blood vessel growth or vascular leakiness, side effects observed with VEGF-C gene therapy due to its activation of VEGFR-2 (Saaristo et al., 2002) . Recently, successful regeneration of a lymphatic network was observed after injection of VEGF-C protein in a surgical lymphedema model in the rabbit ear, indicating the potential use of VEGF-C for the treatment of secondary lymphedema (Skobe et al., 2001) .
Tumor lymphangiogenesis and metastasis
Tumor metastasis to regional lymph nodes represents the first step of tumor dissemination in most skin cancers and also serves as a major prognostic indicator for disease progression. Little is known, however, about the mechanisms how tumor cells gain entry into the lymphatic system, and it has been generally thought that lymphatic invasion only occurs once infiltrating tumor cells happen upon pre-existing peritumoral lymphatic vessels. Recent studies in animal tumor models have now provided direct experimental evidence that increased levels of VEGF-C and/or VEGF-D promote active tumor lymphangiogenesis and lymphatic tumor spread to regional lymph nodes, and that these effects can be suppressed by blocking VEGFR-3 signalling (Mandriota et al., 2001; Skobe et al., 2001; Stacker et al., 2001; He et al., 2002) . Very recently, we have found that VEGF-A also acts as a potent tumor lymphangiogenesis factor and that tumor-derived VEGF-A promotes expansion of the lymphatic network within www.jidonline.org 2173 draining, sentinel lymph nodes, even before these tumors metastasized (Hirakawa et al., 2005) . These novel findings indicate that lymph node lymphangiogenesis might contribute to the further metastatic tumor spread beyond the sentinel lymph node. Importantly, a large number of clinicopathological studies have shown a direct correlation between expression of VEGF-C or VEGF-D by tumor cells and metastatic tumor spread in many human cancers, indicating an important role of lymphangiogenesis also in human tumor progression (Stacker et al., 2002) . Our own recent studies in human cutaneous malignant melanomas demonstrated -for the first time -the presence of both intratumoral and peritumoral lymphangiogenesis (Dadras et al., 2003) . They also showed that primary melanomas that later metastasized were characterized by increased lymphangiogenesis -as compared to non-metastatic tumors -and that the degree of tumor lymphangiogenesis can serve as a novel predictor of lymph node metastasis and overall patient survival, independently of tumor thickness. Tumor lymphangiogenesis also significantly predicted the presence of sentinel lymph node metastases at the time of surgical excision of the primary melanoma . Further studies involving larger numbers of cases are needed to confirm these findings. (Wang et al., 2004; Hong et al., 2004a) . Together, these results provide a molecular explanation for the previously observed controversial results regarding the lineage-specific differentiation of KS cells.
Inflammation and lymphangiogenesis
There is increasing evidence that lymphatic vessels actively participate in acute and chronic inflammation, as well as in the cutaneous response to UVB irradiation. Psoriatic skin lesions are characterized by pronounced lymphatic hyperplasia (Kunstfeld et al., 2004) , and chronic skin inflammation in mice is also associated with LEC proliferation and lymphatic hyperplasia (Kunstfeld et al., 2004) . Furthermore, kidney transplant rejection is frequently accompanied by lymphangiogenesis, and LEC-derived chemokines such as CCL21 might actively promote the inflammatory process (Kerjaschki et al., 2006) . Recently, we found that acute UVB irradiation of the skin results in hyperpermeable, leaky lymphatic vessels that are functionally impaired (Kajiya and Detmar, 2006) . Importantly, blockade of VEGFR-3 resulted in prolonged inflammation and edema after UVB irradiation. Together, these results indicate that lymphatic vessels are not only required to drain inflammation-associated tissue edema, but might also actively participate in the maintenance of chronic inflammatory diseases.
Perspectives
Although traditionally neglected as a topic of scientific study, the lymphatic vascular system has recently received tremendous scientific interest (Brown, 2005) . Owing to a number of recent discoveries, some of the mechanisms controlling the normal and pathological development of the lymphatic vasculature are now being unravelled, and several genetic defects have been identified in patients with lymphedema. The identification of specific markers and growth factors for lymphatic vessels have been instrumental in this advance. The recently proposed concept of tumor lymphangiogenesis and its role in tumor metastasis is of particular importance for the understanding of cancer progression. Further progress in this field will likely lead to a better diagnosis and treatment of a variety of lymphatic disorders but also of certain types of skin cancer and of inflammatory skin diseases.
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